HC Wainwright restated their buy rating on shares of HTG Molecular Diagnostics (NASDAQ:HTGM) in a research report released on Tuesday, January 21st, AnalystRatings.com reports. They currently have a $2.00 price target on the medical research companys stock.<\/p>\n
Several other research firms also recently weighed in on HTGM. Canaccord Genuity set a $1.50 price target on shares of HTG Molecular Diagnostics and gave the stock a buy rating in a research note on Thursday, September 26th. Craig Hallum set a $3.00 price objective on shares of HTG Molecular Diagnostics and gave the company a buy rating in a research note on Friday, September 27th. Cantor Fitzgerald reiterated an overweight rating on shares of HTG Molecular Diagnostics in a report on Friday, October 18th. Finally, ValuEngine raised shares of HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the companys stock. The stock has a consensus rating of Buy and an average price target of $3.13.<\/p>\n
Shares of HTG Molecular Diagnostics stock opened at $0.57 on Tuesday. The business has a 50 day simple moving average of $0.70 and a two-hundred day simple moving average of $0.87. HTG Molecular Diagnostics has a 12 month low of $0.55 and a 12 month high of $3.24. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.21 and a quick ratio of 5.07. The stock has a market capitalization of $33.29 million, a P\/E ratio of -0.98 and a beta of 1.56. <\/p>\n
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.15) earnings per share for the quarter, beating analysts consensus estimates of ($0.16) by $0.01. HTG Molecular Diagnostics had a negative return on equity of 88.60% and a negative net margin of 76.97%. The company had revenue of $5.41 million for the quarter, compared to analyst estimates of $5.63 million. As a group, research analysts anticipate that HTG Molecular Diagnostics will post -0.56 EPS for the current fiscal year. <\/p>\n
Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in HTG Molecular Diagnostics by 20.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,453,160 shares of the medical research companys stock worth $2,413,000 after buying an additional 242,497 shares during the period. BlackRock Inc. increased its position in shares of HTG Molecular Diagnostics by 504.3% during the second quarter. BlackRock Inc. now owns 405,837 shares of the medical research companys stock worth $673,000 after acquiring an additional 338,681 shares during the period. Perkins Capital Management Inc. increased its position in shares of HTG Molecular Diagnostics by 297.1% during the third quarter. Perkins Capital Management Inc. now owns 2,353,153 shares of the medical research companys stock worth $1,564,000 after acquiring an additional 1,760,533 shares during the period. Finally, Citadel Advisors LLC raised its stake in shares of HTG Molecular Diagnostics by 153.9% in the second quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research companys stock valued at $64,000 after acquiring an additional 23,351 shares in the last quarter. Hedge funds and other institutional investors own 38.94% of the companys stock. <\/p>\n
HTG Molecular Diagnostics Company Profile<\/p>\n
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.<\/p>\n
Featured Story: What is diluted earnings per share (Diluted EPS)?<\/p>\n
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.<\/p>\n
<\/p>\n
Go here to read the rest:<\/p>\n
HTG Molecular Diagnostics (HTGM) Buy Rating Reaffirmed at HC Wainwright - Riverton Roll<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" HC Wainwright restated their buy rating on shares of HTG Molecular Diagnostics (NASDAQ:HTGM) in a research report released on Tuesday, January 21st, AnalystRatings.com reports. They currently have a $2.00 price target on the medical research companys stock. Several other research firms also recently weighed in on HTGM Continue reading